Additionally, Zhou et al. identified that myofibroblasts in ccRCC exhibit robust activity and functionality within the TME, with high scores for the stemness gene CD44. They are enriched in OXPHOS and related pathways, and were categorized into subgroups C0, C2 (FXYD2 +), C3 [high—mobility group A (HMGA)1 +], C4 (ITGA1 +), and C5 [pituitary tumor—transforming gene (PTTG)1 +]. The gene discussed is CD44; the disease is nonpapillary renal cell carcinoma.